潘生丁和肠溶阿斯匹林对Ⅱ型糖尿病肾病的临床疗效观察  

The Clinical Use of Anticoagulant in Diabetic Nephropathy (DN) of NIDDM

作　　者：王战建[1] 潘淑芳[2] 李英[1] 顾连方[1] 

机构地区：[1]河北医科大学第三医院,石家庄050051 [2]华北油田医院

出　　处：《中国临床药理学与治疗学》1996年第2期112-114,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的 探讨抗凝剂治疗非胰岛素依赖型糖尿病(NIDDM)微白蛋白尿期(Ⅲ期)时,肾病降低尿微白蛋白排泄率(UAER)的机制.方法 58例NIDDM伴有微白蛋白尿期肾病患者,采用抗凝剂(肠溶阿斯匹林和潘生丁)治疗,治疗前后观察了UAER和高凝状态之间的关系.结果 随着高凝状态的改善,即von willebrand因子(vwF)、血浆纤维结合蛋白(Fg)分别由152.66±36.83%、4.33±1.20g/L降低为128.24±26.20%、3.20±1.28g/L,抗凝血酶第Ⅲ因子(AT-Ⅲ)、血浆纤维结合蛋白(Fn)分别由85.86±19.85%、0.328±0.064g/L升高为98.02±14.48%、0.395±0.076g/L,而UAER由125.66± 85.47μg/min降低为88.13±73.28μg/min,在治疗过程中未观察到有明显副作用.结论 潘生丁和肠溶阿斯匹林用于NIDDM早期肾病为简易、有效和安全治疗方法.Aim The study was aimed to investigate the mechanism of anticoagulant in reducing urinary albumin excreting rate (UAER). Methods Fifty eight patients at their microalbuminuria stage of NIDDM (Ⅲ stage of DN) were treated by anticoagulant (acid acetylsalicylic enter-solubilis and dipyridamole) . The relationship between UAER and hypercoagulability was ob-served before and after treatment. Results It was found that anticoagulant significantly reduced UAER. With improvement of hypercoagulability, UAER was decreased remarkably (P< 0.05) Conclusion Dipyridamole and acid acetylsahicylic entersolubilis are easy, effi-cient and safe drugs for reducing UAER of DN.

关 键 词：抗凝剂 糖尿病肾病 

分 类 号：R977[医药卫生—药品]